Trial Profile
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 21 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 21 Aug 2018 This trial was completed in Czech Republic (end date: 2018-06-13), according to European Clinical Trials Database.
- 28 Jul 2018 This trial has been completed in Germany (end date: 2018-06-13).